News Story: Full Text
Sponsored By
Orbus Therapeutics Inc Clinical Trial for Recurrent Anaplastic Astrocytomas
Please Click On The Above Banner For More Details
Braintumor Website

 

YM BioSciences US unit enrolls first patient for phase II trial of nimotuzumab


Posted on: 02/15/2008

AFX News Limited
YM BioSciences US unit enrolls first patient for phase II trial of nimotuzumab
02.13.08, 7:41 AM ET

 

LONDON (Thomson Financial) - YM BioSciences Inc said its YM BioSciences USA Inc unit has enrolled the first patient in its phase II trial of nimotuzumab in paediatric patients with recurrent diffuse intrinsic pontine glioma (DIPG), a form of inoperable, treatment-resistant brain cancer.

Nimotuzumab is a humanized monoclonal antibody that targets the epidermal growth factor receptor, it said.

The oncology company said eight US paediatric clinical centres and two Canadian centres will be participating in the single-arm trial, which is designed to enrol 44 patients with DIPG who will be treated with nimotuzumab as monotherapy.

TFN.newsdesk@thomson.com

kal/am


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740